论文部分内容阅读
目的探讨桂枝茯苓胶囊联合米非司酮治疗围绝经期子宫肌瘤患者的临床疗效及其安全性。方法选取万安县人民医院2014年1月—2016年1月收治的子宫肌瘤患者94例,随机分为单药组和联合组,各47例。单药组患者给予米非司酮治疗,联合组患者在单药组基础上加服桂枝茯苓胶囊,两组患者均持续治疗3个月。比较两组患者的临床疗效,治疗前后性激素水平[雌二醇(E_2)、促卵泡激素(FSH)、黄体生成素(LH)、孕酮(P)]、子宫体积及肌瘤体积,并比较两组患者治疗期间不良反应发生情况。结果联合组患者临床疗效优于单药组(P<0.05)。治疗前,两组患者E_2、FSH、LH、P水平及子宫体积、肌瘤体积比较,差异无统计学意义(P>0.05);治疗后,联合组患者E_2、FSH、LH、P水平低于单药组,子宫体积、肌瘤体积小于单药组(P<0.05)。两组患者治疗期间均未出现严重不良反应。结论桂枝茯苓胶囊联合米非司酮治疗围绝经期子宫肌瘤临床疗效确切,可有效降低患者血清性激素水平,缩小子宫及肌瘤体积,且安全性高。
Objective To investigate the clinical efficacy and safety of Guizhi Fuling Capsule combined with mifepristone in the treatment of peri-menopausal uterine fibroids. Methods 94 patients with uterine leiomyoma who were treated in Wan’an County People’s Hospital from January 2014 to January 2016 were randomly divided into single drug group and combined group, with 47 cases in each group. Patients in monotherapy group were treated with mifepristone. Patients in combination group were treated with Guizhi Fuling capsules on the basis of single drug group, and patients in both groups were treated for 3 months continuously. The clinical efficacy of the two groups was compared. The levels of sex hormones (E2, FSH, LH and progesterone), uterine volume and myoma volume before and after treatment were compared. Two groups of patients during treatment of adverse reactions occurred. Results The clinical efficacy of combination group was better than that of single drug group (P <0.05). Before treatment, E_2, FSH, LH, P levels, uterine volume and fibroid volume in the two groups had no significant difference (P> 0.05). After treatment, the levels of E_2, FSH, LH and P in the combined group were lower than Monotherapy group, uterine volume, fibroids volume was smaller than the single drug group (P <0.05). Two groups of patients during the treatment did not appear serious adverse reactions. Conclusion Guizhi Fuling Capsule combined with mifepristone treatment of perimenopausal uterine fibroids clinically effective, can effectively reduce the serum levels of sex hormones, reduce the volume of uterine and fibroids, and high safety.